Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fostamatinib for residual disease after chemoimmunotherapy in chronic lymphocytic leukemia
2009-009034-32Phase 2Terminated
- Sponsor
- Policlinico Gemelli
- Start
- Apr 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fostamatinib in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), sponsored by Policlinico Gemelli. Primary endpoints: Tolerability and Progression-free survival. Started Apr 2009; status: terminated.
02
Drugs
fostamatinib
03
Conditions
chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL)
Beyond the preview
Go deeper on 2009-009034-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009034-32.